Tushar R. Vora, MD, MBA

Accomplished physician and healthcare executive with over 20years years of clinical and administrative experience. Board-certified in cardiology, with proven leadership in managing multidisciplinary teams, optimizing healthcare delivery, and driving clinical quality improvement initiatives including use of AI in health care.

• Recognized for result oriented leadership, strategic planning, and operational excellence across both hospital and outpatient settings. Demonstrated success in negotiating complex physician contracts with hospital organizations and payors, as well as leading diverse multidisciplinary teams to ensure efficient clinical workflows and superior patient outcomes.
• Initiated and creating workflows to optimize use of AI applications in outpatient and inpatient setting.
• Exploring new applications of Agentic AI in health care

• Member of American Society of Echocardiography
• Member of Society of Cardiac CT
• Member of American College of Cardiology
• Member of Hennepin Medical Society
• Member of Minnesota Medical Association
• Fellow of American College of Cardiology
• Fellow of the American Society of Echocardiography

• 1998 USMLE
• 2001 Diplomat of American Board of Internal Medicine
• 2002-2012 Board Certified in Nuclear Cardiology
• 2004-2014 Board Certified in Cardiovascular Diseases
• 2014-2024 Recertified, Cardiovascular Disease
• 2007-2017 Board Certified, National Board of Echocardiography
• 2017-2027 Recertified, National Board of Echocardiography
• 2010-2020 Board Certified, Certification Board of Cardiovascular CT

• 1. Tushar Vora, Prashant Pendyala, Holger Schuneman, Angel Lopez Candales. Prolongation of QTc Interval during Dobutamine Stress Echocardiography: A marker for ischemia. Coronary Artery Disease, 2003.
• 2. Vora Tushar, Thomas Lajos, Angel Lopez Candales. Unusual Presentation of Papillary Fibroelastoma: Utility of serial Transesophageal Echocardiograms, published in journal Echocardiography.
• 1. Trans-esophageal evaluation for cardiac source of emboli in patients with ischemic cerebrovascular event. Vijayasekaran S, Vora T, Pendyala P, Lopez-Candales A. Poster Presentation at the 2001 Annual American Society of Echocardiography Meeting.
• 2. Exercise Tolerance Improves after Intermittent Inotrope Therapy in Out-Patients with Advanced Heart Failure. Tushar R Vora, William. J. Gibbons, Angel Lopez-Candales. Journal of Cardiac Failure, 2001;7(3):21. Poster Presentation at the Fifth Annual Heart Failure Society of America Meeting, Washington DC, September 2001.
• 3. Intermittent Inotrope Infusion Therapy Leads to Increased QT Duration and QT Dispersion. Tushar R Vora, Sridhar Vijayasekaran, Prashant Pendyala, Angel Lopez Candales. Journal of Cardiac Failure, 2001;7(3):65. Poster Presentation at the Fifth Annual Heart Failure Society of America Meeting, Washington DC, September 2001.
• 4. Relationship between Depression and Congestive Heart Failure among stable Patients in Outpatient Setting. Tushar Vora, Sridhar Vijayasekaran, Angel Lopez Candales. Journal of Cardiac Failure, 2001;7(3):67. Poster Presentation at the Fifth Annual Heart Failure Society of America Meeting, Washington DC, September 2001.
• 5. Outpatient Intermittent Inotrope Therapy in patients with Advanced Heart Failure: A Double-Blind Randomized Study. Tushar R Vora, Chris Carron, Paula Simmons, Angel-Lopez Candales. Chest, 2001;120(4):179S. Accepted for oral presentation at the Sixty-Seventh Annual Meeting of American College of Chest Physicians, November 2001.
• 6. Does resting pulmonary function improve after outpatient inotrope therapy in severe heart failure? Tushar R Vora, William J Gibbons, Angel Lopez Candales. Chest, 2001;120(4):181S. Oral Presentation at the Sixty-Seventh Annual Meeting of American College of Chest Physicians, November 2001.
• 7. Patient Characteristics and the type of Cardiac Source of Emboli: A Transesophageal Echocardiographic Study. Sridhar Vijayasekaran, Tushar Vora, Prashant Pendyala, Angel-Lopez Candales. Accepted for oral presentation at the Sixty-Seventh Annual Meeting of American College of Chest Physicians, November 2001;120(4):142S.
• 8. QTc prolongation as a marker of myocardial ischemia and propensity of ventricular premature complexes during Dobutamine Stress Echocardiogram. Prashant Pendyala, Holger Schuneman, Tushar Vora, Angel Lopez Candales. Presented at the 2001 Regional Meeting of the American College of Physicians- American Society of Internal Medicine at New York.
• 9. Does congestive heart failure cause cognitive impairment? Sridhar Vijayasekaran, Tushar Vora, Angel Lopez Candales. Oral Presentation at the Annual Scientific Meeting of the American Heart Association held in November 2001.

• Level II Echocardiography
• Level III Cardiac and Vascular Computerized Tomography
• Level II Nuclear Cardiology
• Level II Cardiac MRI
• Diagnostic Coronary Angiography via both the Femoral and Radial Routes; Right Heart Catheterization; Temporary transvenous pacemaker insertion, Intra-aortic Balloon Pump Insertion

• Fairview Southdale Hospital 6401 France Avenue South Edina, MN 55435
• Fairview Northland Regional Hospital 919 Northland Drive Princeton MN 55371
• Fairview Ridges Hospital 201 East Nicollet Avenue Burnsville, MN 55337
• Fairview Lakes Regional Medical Center 5200 Fairview Blvd Wyoming, MN 55092
• University of Minnesota Medical Center, Fairview 500 Harvard St. Minneapolis, MN 55455

• 1999-Present Clinical Assistant Instructor of Internal Medicine
• 1995- 1999 State University of New York at Buffalo Supervised and taught medical students and residents actively involved in teaching medical students and interns during the residency training in Internal Medicine at the Seth G.S. Medical College, India
• 2005- Present Clinical Supervision of Weekend Cardiovascular Fellows

• Minnesota # 46307
• License and permanent registration to practice Medicine in India
• ECFMG indefinite certificate
• Limited permit to practice Medicine in State of New York

• Co-investigator for the following trial(s):
• IMPROVE-IT Trial, “A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial – IMPROVE-IT) 2007-Present